Of the downregulated lncRNAs, PTENP1 and GNG12-AS1, in particular, evinced not only remarkably reduced expression in the cancer samples compared to the benign samples, but also showed associations with several clinical parameters including patient outcomes (improved for the high-expression subgroups), tumor grades (both lncRNAs) and stages (GNG12-AS1), thus underlining their tumor suppressor effects in breast cancer; this finding is also supported by the results of other researchers. This evidence concerns the gene PTENP1 and breast carcinoma.